Concepedia

SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

Paul Nathan, A. Needham, P. Corrie, Sarah Danson, Jonathan J. Evans, Sebastian Ochsenreither, S. Kumar, Andrew Goodman, J. Larkin, Ioannis Karydis,

Annals of Oncology · 2019 · 15 citations · 0 references

DOIFull text

Open access

Concepts